Source:http://linkedlifedata.com/resource/pubmed/id/16866989
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2006-7-26
|
| pubmed:abstractText |
Chromogenic in situ hybridization (CISH) was used to detect amplification of the epidermal growth factor receptor (EGFR) gene in tissue microarrays of tumours derived from 287 patients with grade II-IV diffuse astrocytomas. Amplification was found in 32% of the tumours with a highly significant association with histological grade (4% in grade II, 21% in grade III and 39% in grade IV; P < 0.001). Amplification of the EGFR gene was more common in primary than in secondary glioblastomas (41%vs. 16%, P = 0.033). Overexpression of EGFR mRNA and protein (wild-type and vIII variant) was found to correlate with EGFR gene amplification (P = 0.028, P = 0.035 and P = 0.014 respectively), but wild-type EGFR protein was also frequently overexpressed in tumours without EGFR gene amplification. Patients with older age (P < 0.001) and tumours with lack of p53 overexpression (P = 0.03) and higher apoptosis rate (P < 0.001) had significantly more EGFR gene amplifications than their counterparts. No such correlation with apoptosis was found in glioblastomas. The survival of patients with EGFR gene-amplified grade III tumours was significantly shorter than in those with grade III non-amplified tumours (P = 0.03). No such difference was noted in glioblastomas (grade IV tumours). Our data verify the central role of EGFR in the pathobiology of astrocytic tumours, and highlight the advantages of CISH as a simple and practical assay to screen for EGFR gene amplification in astrocytic tumours.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Chromogenic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0305-1846
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
32
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
441-50
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:16866989-Adolescent,
pubmed-meshheading:16866989-Adult,
pubmed-meshheading:16866989-Age Factors,
pubmed-meshheading:16866989-Aged,
pubmed-meshheading:16866989-Aged, 80 and over,
pubmed-meshheading:16866989-Apoptosis,
pubmed-meshheading:16866989-Astrocytoma,
pubmed-meshheading:16866989-Brain Neoplasms,
pubmed-meshheading:16866989-Child,
pubmed-meshheading:16866989-Child, Preschool,
pubmed-meshheading:16866989-Chromogenic Compounds,
pubmed-meshheading:16866989-Female,
pubmed-meshheading:16866989-Gene Amplification,
pubmed-meshheading:16866989-Humans,
pubmed-meshheading:16866989-Immunohistochemistry,
pubmed-meshheading:16866989-In Situ Hybridization,
pubmed-meshheading:16866989-Male,
pubmed-meshheading:16866989-Middle Aged,
pubmed-meshheading:16866989-Protein Array Analysis,
pubmed-meshheading:16866989-RNA, Messenger,
pubmed-meshheading:16866989-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16866989-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16866989-Survival Analysis,
pubmed-meshheading:16866989-Survival Rate,
pubmed-meshheading:16866989-Tumor Suppressor Protein p53
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.
|
| pubmed:affiliation |
Department of Pathology, Tampere University Hospital, Tampere, Finland. sally.jarvela@sci.fi
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|